腹膜后局限性CastLeman病4例报告并文献复习

杨冬园; 周四维

腹膜后局限性CastLeman病4例报告并文献复习

杨冬园^1, ,,
周四维²

- 1. 四川省第四人民医院泌尿外科(成都, 610016);
- 2. 华中科技大学同济医学院附属同济医院泌尿外科

详细信息

通讯作者: 杨冬园,E-mail:yangdy6611@163.com

中图分类号: R737

收稿日期: 2012-06-19

Retroperitoneal local CastLeman's disease: 4 case reports and literature review

YANG Dongyuan^1, ,,
ZHOU Siwei²

- 1. Department of Urology, Sichuan Province No. 4 People's Hospital, Chengdu, 610016, China;
- 2. Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

More Information

Corresponding author: YANG Dongyuan, E-mail: yangdy6611@163.com

Received Date: 19 June 2012

摘要

摘要: 目的： 报告偶然发现的4例腹膜后局限性CastLeman病，并结合文献复习，以提高对该疾病的认识及诊疗水平。方法：回顾性分析4例术前未能明确诊断的后腹膜占位性病变病例，经手术切除，术后病理证实为较少见的局限性CastLeman病。结果：4例均经手术完整切除肿瘤，未行辅助治疗，随访7个月~4年2个月，4例患者均无瘤存活，未见肿瘤复发。结论：腹膜后CastLeman病临床症状不典型，术前实验室及影像学检查无特异性，常易误诊。手术探查切除肿瘤为首选治疗方法，疗效较好，最终明确诊断有赖于病理学检查。
- CastLeman病 /
- 诊断 /
- 治疗
Abstract: Objective: We reported the incidentally found 4 cases of retroperitoneal the local CastLeman's disease and undertook a literature review to improve the diagnosis and treatment of the disease.Method:Retrospectively analyzed 4 cases with retroperitoneal mass which failed to confirm the diagnosis before surgery. After surgical resection, the pathological results were local CastLeman's disease.Result: All 4 cases received complete surgical resection of the tumor. No adjuvant therapy was administrated. Follow-up ranged form 4 months to 4 years and 2 months. No recurrence was observed.Conclusion: Retroperitoneal CastLeman's disease has no typical clinical findings. It may pose a diagnose dilemma because of its lack of specific lab test and distinguish radiographic features. Surgical exploration to remove the tumor is the preferred treatment with fair outcome. Eventually confirming diagnosis depends on the pathological examination.
- CastLeman disease /
- diagnosis /
- treatment

HTML全文

参考文献(11)

[1]	赵晨晖,周文龙,张志伟,等.腹膜后局限型Castleman病2例及文献复习[J].现代泌尿生殖肿瘤杂志,2011,3(2),77-79.
[2]	宋科,蓝儒竹.Castleman病1例报告[J].现代泌尿生殖肿瘤杂志,2011,3(6),360-360.
[3]	肖峻, 陈凌武, 郑伏甫. 腹膜后局限性Castleman病误诊嗜铬细胞瘤4例并文献复习[J]. 现代泌尿生殖肿瘤杂志, 2012, 4(1):10-12.
[4]	Powles T, Stebbing J, Montoto S, et al. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease[J]. Blood, 2007, 110:4132-4133.
[5]	Chen C H, Liu H C, Tung K Y, et al. Surgical outcome of superficial and deep Castleman disease[J]. ANZ J Surg, 2007, 77:339-343.
[6]	Kawabata H, Tomosugi N, Kanda J, et al. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease[J]. Haematologica, 2007, 92:857-858.
[7]	Beck J T, Hsu S M, Wijdenes J, et al. Brief report:alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody[J]. N Engl J Med, 1994, 330:602-605.
[8]	Dham A, Peterson B A. Castleman disease[J]. Curr Opin Hematol, 2007, 14:354-359.
[9]	Chronowski G M, Ha C S, Wilder R B, et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy[J]. Cancer, 2001, 92:670-676.
[10]	Bestawros A, Michel R, Séguin C, et al. Multicentric Castleman's disease treated with combination chemotherapy and rituximab in four HIV-positive men:a case series[J]. Am J Hematol, 2008, 83:508-511.
[11]	Matsuyama M, Suzuki T, Tsuboi H, et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease[J]. Intern Med, 2007, 46:771-774.